Active, not recruitingPhase 2NCT02983578

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Studying Constitutional mismatch repair deficiency syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
David S Hong
M.D. Anderson Cancer Center
Intervention
Danvatirsen(drug)
Enrollment
39 enrolled
Eligibility
18 years · All sexes
Timeline
20172025

Study locations (1)

Collaborators

National Cancer Institute (NCI) · AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02983578 on ClinicalTrials.gov

Other trials for Constitutional mismatch repair deficiency syndrome

Additional recruiting or active studies for the same condition.

See all trials for Constitutional mismatch repair deficiency syndrome

← Back to all trials